sponsored
PatientsVille.com Logo

PatientsVille

RECLAST Medical Research Studies

Up-to-date List of RECLAST Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest RECLAST Medical Research Studies

Rank Status Study
1 Not yet recruiting The Use of Zoledronic Acid to Complex Regional Pain Syndrome
Condition: Complex Regional Pain Syndromes
Interventions: Drug: Zoledronic acid;   Drug: Placebo
Outcome Measures: Pain measured on Visual Analog Scale;   Lower Limbs vertical force on Wii platform;   American Orthopaedic Foot and Ankle Scale (AOFAS);   36-Item Short Form Health Survey (SF-36)
2 Recruiting Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Condition: Mesothelioma
Intervention: Drug: Zometa (zoledronic acid)
Outcome Measures: Evaluation of the tumor response rate following zoledronic acid;   Evaluation of the duration of tumor response
3 Recruiting Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Drug: zoledronic acid;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
Outcome Measures: Changes in biomarkers of tumor growth and metastasis in women with newly diagnosed ER and/or PR positive invasive ductal breast cancer receiving zoledronic acid;   Changes in immunologic function after a single dose of zoledronic acid;   Changes in the expression of tumor markers important to breast cancer progression and metastasis in women receiving zoledronic acid
4 Recruiting Zoledronic Acid in Acute Spinal Cord Injury
Condition: Complete Traumatic Spinal Cord Injury
Interventions: Drug: Zoledronic acid;   Drug: normal saline 0.9%
Outcome Measures: change in bone mineral density;   Biomarkers of bone formation and resorption;   safety and tolerability of zoledronic acid
5 Unknown  Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
Condition: Osteosarcoma
Interventions: Drug: Zoledronic acid;   Drug: Standard chemotherapy
Outcome Measure: histological response disease free interval
6 Recruiting The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Condition: Osteogenesis Imperfecta
Interventions: Drug: Zoledronic acid;   Drug: Teriparatide;   Drug: placebo zoledronic acid;   Drug: placebo teriparatide
Outcome Measures: Bone Mineral Density (BMD);   Fracture risk
7 Recruiting Bone Loss Treatment From Adjuvant Zoledronate Efficacy
Conditions: Breast Neoplasms;   Bone Loss
Intervention: Drug: Zoledronate
Outcome Measures: Change from Baseline in Bone Mineral Density;   Bone metastasis rate;   Disease-Free Survival
8 Recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
Outcome Measures: Time to the first on-study skeletal related event (SRE) (non-inferiority test);   Time to the first-and-subsequent SRE (superiority test, using multiple event analysis);   Time to the first on-study SRE (superiority test)
9 Recruiting Effect of the Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Who Have Relapsed After 1-3 Prior Lines of Therapy
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Zoledronic Acid;   Drug: Dexamethasone
Outcome Measures: Bone Mineral Density (BMD);   Bone mineral density (BMD);   Serum values of bone-specific alkaline phosphatase, osteocalcin and C-terminal cross-linking telopeptides of collagen type-I;   Bone pain;   Skeletal-related events (SRE: pathologic fractures, need for bone radiation therapy or surgery);   Improvement of osteolytic lesions
10 Not yet recruiting Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
Conditions: Malignant Neoplasm;   Musculoskeletal Complications
Interventions: Drug: zoledronic acid;   Other: pharmacological study
Outcome Measures: Plasma concentrations of Zol collected at visits 2, 3, 4, and 5;   Urine concentrations of Zol collected at visits 2, 3, 4, and 5;   Jawbone tissue concentrations of Zol collected during surgical treatment for BRONJ;   Identify potential risk factors for BRONJ
11 Recruiting Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Zoledronic Acid;   Biological: Aldesleukin
Outcome Measures: Evaluate the safety and toxicity of zoledronic acid and aldesleukin;   Evaluate the biologic function of autologous expanded/activated gamma delta T cells in neuroblastoma patients receiving therapy with zoledronic acid and aldesleukin;   uoEvaluate immune phenotype of in vivo expanded/activated autologous gamma delta T cells;   To document tumor response in patients with measurable disease.;   Determine the ability of in vivo expanded/activated gamma delta T cells to infiltrate neuroblastoma tissue using immunohistochemical techniques when post-therapy specimens are available.
12 Recruiting The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Pamidronate;   Drug: Zoledronic acid;   Drug: placebo
Outcome Measures: sCTX values;   Palliative response
13 Recruiting Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
Conditions: Giant Cell Tumor of Bone;   Osteoclastoma
Intervention: Drug: Zoledronic acid
Outcome Measures: Determine if adjuvant zoledronic acid improves the 2 year recurrence rate of 'high risk' GCT as compared to standard care;   Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT;   Determine the relapse free survival
14 Recruiting N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
Outcome Measures: Determination of toxicities and feasibility of the combination of bolus plus metronomic cyclophosphamide and zoledronic acid with and without bevacizumab when given to children with refractory or recurrent high risk neuroblastoma.;   Evaluation of response within the confines of a phase I study.;   Analysis of Circulating Endothelial Cells, Circulating Factors, Gene expression and Bone Metabolism Studies.
15 Recruiting FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)
Condition: Osteoporosis
Interventions: Other: FES-Rowing;   Drug: Zoledronic acid
Outcome Measures: Improvement of bone mass as measured by sequential evaluation of bone density and bone structure;   Validation of DXA Scanning in patients with SCI
16 Recruiting 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Condition: Osteoporosis
Intervention: Drug: zoledronic acid
Outcome Measures: Safety of zoledronic acid for the treatment of osteoporotic children treated with glucocorticoids for chronic inflammatory conditions by adverse event collection and laboratory results monitoring.;   Change from baseline in LS areal BMD Z-score at Month 18 and 24 by core treatment group by dual energy x-ray absorptiometry (DXA).;   Change from baseline in LS and total body BMC by core treatment group by DXA.;   Change in biochemical marker values (serum P1NP, BSAP, NTx and TRAP-5b) from baseline.;   Change in the number of new clinical vertebral fractures and new morphometric vertebral fractures.;   To evaluate the change from baseline (Visit 1 of the Core study) in pain using the Faces Pain Scale-Revised (FPS-R)by core treatment group.
17 Unknown  Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Condition: Hepatocellular Carcinoma
Intervention: Drug: Sorafenib and Zoledronic Acid
Outcome Measures: numbers of adverse events;   Overall survival (OS), time to progression (TTP)
18 Recruiting Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Zoledronic Acid and Aromatase Inhibitors
Outcome Measures: therapeutic assessment;   Adverse reactions and disease-free survival
19 Recruiting HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: tamoxifen;   Drug: triptorelin;   Drug: letrozole;   Drug: zoledronic acid
Outcome Measures: disease free survival in premenopausal patients;   bone mineral density;   Bone mineral density measured;   disease free survival in postmenopausal patients;   overall survival;   toxicity of letrozole + triptorelin and letrozole + zoledronic acid + triptorelin in premenopausal patients
20 Not yet recruiting Zoledronic Acid in Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: Zoledronic acid
Outcome Measure: Sharp van der Heijde index

These studies may lead to new treatments and are adding insight into RECLAST etiology and treatment.

A major focus of RECLAST research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss RECLAST